Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 48, 2016, Pages E7749-E7758

  Rangel, Roberto ^a   Lee, Song Choon ^b   Ban, Kenneth Hon Kim ^b,c   Guzman Rojas, Liliana ^a   Mann, Michael B ^a   Newberg, Justin Y ^a   Kodama, Takahiro ^a   McNoe, Leslie A ^d   Selvanesan, Luxmanan ^d   Ward, Jerrold M ^b,f   Rust, Alistair G ^e,g   Chin, Kuan Yew ^b   Black, Michael A ^d   Jenkins, Nancy A ^a,b   Copeland, Neal G ^a,b  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^f Global VetPathology   (United States)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; Metastasis; Sleeping Beauty; TRPS1; Tumor suppressors

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; DNA BINDING PROTEIN; PROTEIN C FOS; PTEN PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FRA 1; TRPS1 PROTEIN, HUMAN;

ADENOSQUAMOUS CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL LIKE BREAST CANCER; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; METASTATIC BREAST CANCER; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; SERPINB2 GENE; SERPINE1 GENE; TRANSPOSON; TRIPLE NEGATIVE BREAST CANCER; TRPS1 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; ANIMAL; DISEASE EXACERBATION; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MISSENSE MUTATION; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SECONDARY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA TRANSPOSABLE ELEMENTS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENES, TUMOR SUPPRESSOR; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, TRANSGENIC; MUTAGENESIS; MUTATION, MISSENSE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-FOS; PTEN PHOSPHOHYDROLASE; TRANSCRIPTION FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84999268232     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1613859113     Document Type: Article

References (74)

1. Banerji S, et al. (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486(7403):405-409.
2. Curtis C, et al.; METABRIC Group (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346-352.
3. Ellis MJ, et al. (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486(7403):353-360.
4. Stephens PJ, et al.; Oslo Breast Cancer Consortium (OSBREAC) (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403):400-404.
5. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70.
6. Arnedos M, et al. (2015) Precision medicine for metastatic breast cancer-Limitations and solutions. Nat Rev Clin Oncol 12(12):693-704.
7. Couch FJ, Nathanson KL, Offit K (2014) Two decades after BRCA: Setting paradigms in personalized cancer care and prevention. Science 343(6178):1466-1470.
8. Shiovitz S, Korde LA (2015) Genetics of breast cancer: A topic in evolution. Ann Oncol 26(7):1291-1299.
9. Chalhoub N, Baker SJ (2009) PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4:127-150.
10. Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13(5):283-296.
11. Engebraaten O, Vollan HK, Børresen-Dale AL (2013) Triple-negative breast cancer and the need for new therapeutic targets. Am J Pathol 183(4):1064-1074.
12. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938-1948.
13. Shah SP, et al. (2012) The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature 486(7403):395-399.
14. Li Y, et al. (2001) Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol 2:2.
15. Li G, et al. (2002) Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 129(17):4159-4170.
16. Stambolic V, et al. (2000) High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 60(13):3605-3611.
17. Saal LH, et al. (2008) Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 40(1):102-107.
18. Bard-Chapeau EA, et al. (2014) Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet 46(1):24-32.
19. Dorr C, et al. (2015) Transposon mutagenesis screen identifies potential lung cancer drivers and CUL3 as a tumor suppressor. Mol Cancer Res 13(8):1238-1247.
20. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA (2005) Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 436(7048):221-226.
21. Mann KM, et al.; Australian Pancreatic Cancer Genome Initiative (2012) Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci USA 109(16):5934-5941.
22. V600E) melanoma. Nat Genet 47(5):486-495.
23. Moriarity BS, et al. (2015) A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet 47(6):615-624.
24. Rahrmann EP, et al. (2013) Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet 45(7):756-766.
25. Riordan JD, et al. (2013) Identification of rtl1, a retrotransposon-derived imprinted gene, as a novel driver of hepatocarcinogenesis. PLoS Genet 9(4):e1003441.
26. Takeda H, et al. (2015) Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression. Nat Genet 47(2):142-150.
27. Dupuy AJ, et al. (2009) A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res 69(20):8150-8156.
28. Keng VW, et al. (2005) Region-specific saturation germline mutagenesis in mice using the Sleeping Beauty transposon system. Nat Methods 2(10):763-769.
29. Moumen M, et al. (2012) The proto-oncogene Myc is essential for mammary stem cell function. Stem Cells 30(6):1246-1254.
30. Chiche A, et al. (2013) Somatic loss of p53 leads to stem/progenitor cell amplification in both mammary epithelial compartments, basal and luminal. Stem Cells 31(9):1857-1867.
31. Parker JS, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160-1167.
32. Anjomshoaa A, et al. (2008) Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer. Br J Cancer 99(6):966-973.
33. March HN, et al. (2011) Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet 43(12):1202-1209.
34. Brett BT, et al. (2011) Novel molecular and computational methods improve the accuracy of insertion site analysis in Sleeping Beauty-induced tumors. PLoS One 6(9):e24668.
35. Futreal PA, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4(3):177-183.
36. Kandoth C, et al. (2013) Mutational landscape and significance across 12 major cancer types. Nature 502(7471):333-339.
37. Ciriello G, et al.; TCGA Research Network (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163(2):506-519.
38. Gao J, et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1.
39. Aceto N, et al. (2014) Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158(5):1110-1122.
40. Chen EY, et al. (2013) Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14:128.
41. Anastas JN, Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13(1):11-26.
42. Wang X, et al. (2008) Association of genetic variation in genes implicated in the β-catenin destruction complex with risk of breast cancer. Cancer Epidemiol Biomarkers Prev 17(8):2101-2108.
43. Malik TH, et al. (2001) Transcriptional repression and developmental functions of the atypical vertebrate GATA protein TRPS1. EMBO J 20(7):1715-1725.
44. van den Bemd GJ, Jhamai M, Brinkmann AO, Chang GT (2003) The atypical GATA protein TRPS1 represses androgen-induced prostate-specific antigen expression in LNCaP prostate cancer cells. Biochem Biophys Res Commun 312(3):578-584.
45. Momeni P, et al. (2000) Mutations in a new gene, encoding a zinc-finger protein, cause tricho-rhino-phalangeal syndrome type I. Nat Genet 24(1):71-74.
46. Asou N, et al. (2007) Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia. Blood 109(9):4023-4027.
47. Chang GT, Jhamai M, van Weerden WM, Jenster G, Brinkmann AO (2004) The TRPS1 transcription factor: Androgenic regulation in prostate cancer and high expression in breast cancer. Endocr Relat Cancer 11(4):815-822.
48. Hong J, Sun J, Huang T (2013) Increased expression of TRPS1 affects tumor progression and correlates with patient prognosis of colon cancer. BioMed Res Int 213:1-6.
49. Liang H, et al. (2012) Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 22(11):2120-2129.
50. Radvanyi L, et al. (2005) The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci USA 102(31):11005-11010.
51. Chen JQ, et al. (2013) Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. Ann Oncol 24(10):2534-2542.
52. Stinson S, et al. (2011) TRPS1 targeting by miR-221/222 promotes the epithelial-tomesenchymal transition in breast cancer. Sci Signal 4(177):ra41.
53. Pavón MA, et al. (2015) Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients. Oncotarget 6(30):29016-29033.
54. Sang Y, et al. (2015) TEL2 suppresses metastasis by down-regulating SERPINE1 in nasopharyngeal carcinoma. Oncotarget 6(30):29240-29253.
55. Valiente M, et al. (2014) Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156(5):1002-1016.
56. Fantauzzo KA, Christiano AM (2012) Trps1 activates a network of secreted Wnt inhibitors and transcription factors crucial to vibrissa follicle morphogenesis. Development 139(1):203-214.
57. Napierala D, et al. (2005) Mutations and promoter SNPs in RUNX2, a transcriptional regulator of bone formation. Mol Genet Metab 86(1-2):257-268.
58. Napierala D, et al. (2012) Transcriptional repression of the Dspp gene leads to dentinogenesis imperfecta phenotype in Col1a1-Trps1 transgenic mice. J Bone Miner Res 27(8):1735-1745.
59. Suemoto H, et al. (2007) Trps1 regulates proliferation and apoptosis of chondrocytes through Stat3 signaling. Dev Biol 312(2):572-581.
60. Gyo{combining double acute accent}rffy B, Surowiak P, Budczies J, Lánczky A (2013) Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 8(12):e82241.
61. Ringnér M, Fredlund E, Häkkinen J, Borg Å, Staaf J (2011) GOBO: Gene expression-based outcome for breast cancer online. PLoS One 6(3):e17911.
62. Widmann C, Johnson NL, Gardner AM, Smith RJ, Johnson GL (1997) Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1. Oncogene 15(20):2439-2447.
63. Creighton CJ, et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106(33):13820-13825.
64. Eckhardt BL, et al. (2005) Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 3(1):1-13.
65. Wagenblast E, et al. (2015) A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature 520(7547):358-362.
66. Duffy MJ (2004) The urokinase plasminogen activator system: Role in malignancy. Curr Pharm Des 10(1):39-49.
67. Harbeck N, et al. (2004) Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: Novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 91(3):450-456.
68. Bajou K, et al. (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4(8):923-928.
69. Ramirez A, et al. (2004) A keratin K5Cre transgenic line appropriate for tissue-specific or generalized Cre-mediated recombination. Genesis 39(1):52-57.
70. Starr TK, et al. (2009) A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323(5922):1747-1750.
71. R Core Team (2015) R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria). Available at www.R-project.org/.
72. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy-Analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20(3):307-315.
73. Parman C, Halling C, Gentleman R (2016) affyQCReport: QC Report Generation for affyBatch Objects, R package version 1.44.0. Available at bioconductor.org/packages/affyQCReport/. Accessed October 14, 2014.
74. Soon WW, et al. (2011) Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. EMBO Mol Med 3(8):451-464.